[go: up one dir, main page]

DK3725786T3 - KRYSTALLINSK FORM OG SALTFORM AF TGF-ßRI INHIBITOR OG FORBEREDELSESMETODE FOR DETTE - Google Patents

KRYSTALLINSK FORM OG SALTFORM AF TGF-ßRI INHIBITOR OG FORBEREDELSESMETODE FOR DETTE Download PDF

Info

Publication number
DK3725786T3
DK3725786T3 DK18888487.8T DK18888487T DK3725786T3 DK 3725786 T3 DK3725786 T3 DK 3725786T3 DK 18888487 T DK18888487 T DK 18888487T DK 3725786 T3 DK3725786 T3 DK 3725786T3
Authority
DK
Denmark
Prior art keywords
ßri
tgf
inhibitor
preparation
crystalline form
Prior art date
Application number
DK18888487.8T
Other languages
English (en)
Inventor
Lifang Wu
Huijun He
Jianyu Lu
Charles Z Ding
Lihong Hu
Weidong Li
Shenyi Shi
Jian Li
Shuhui Chen
Original Assignee
Genfleet Therapeutics Shanghai Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genfleet Therapeutics Shanghai Inc filed Critical Genfleet Therapeutics Shanghai Inc
Application granted granted Critical
Publication of DK3725786T3 publication Critical patent/DK3725786T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • A61K31/4161,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK18888487.8T 2017-12-13 2018-12-13 KRYSTALLINSK FORM OG SALTFORM AF TGF-ßRI INHIBITOR OG FORBEREDELSESMETODE FOR DETTE DK3725786T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201711331447 2017-12-13
PCT/CN2018/120905 WO2019114792A1 (zh) 2017-12-13 2018-12-13 一种TGF-βRI抑制剂的晶型、盐型及其制备方法

Publications (1)

Publication Number Publication Date
DK3725786T3 true DK3725786T3 (da) 2023-11-27

Family

ID=66818947

Family Applications (1)

Application Number Title Priority Date Filing Date
DK18888487.8T DK3725786T3 (da) 2017-12-13 2018-12-13 KRYSTALLINSK FORM OG SALTFORM AF TGF-ßRI INHIBITOR OG FORBEREDELSESMETODE FOR DETTE

Country Status (13)

Country Link
US (1) US11236112B2 (da)
EP (1) EP3725786B1 (da)
JP (1) JP7028977B2 (da)
KR (1) KR102507328B1 (da)
CN (1) CN111479809B (da)
AU (1) AU2018383853B2 (da)
BR (1) BR112020011602A2 (da)
CA (1) CA3085498C (da)
DK (1) DK3725786T3 (da)
ES (1) ES2960412T3 (da)
PT (1) PT3725786T (da)
RU (1) RU2750702C1 (da)
WO (1) WO2019114792A1 (da)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112851695A (zh) * 2021-01-27 2021-05-28 复旦大学附属华山医院 甲酰胺类化合物在制备抗脊索肿瘤药物中的应用及试剂盒
CN112759592A (zh) * 2021-02-01 2021-05-07 无锡鸣鹭医药科技有限公司 一种6-碘[1,2,3]三唑并[1,5-a]吡啶的合成方法
CN115969801B (zh) * 2023-03-21 2023-08-25 劲方医药科技(上海)有限公司 用于癌症的药物组合物及其制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3038004A (en) * 1958-04-18 1962-06-05 Burroughs Wellcome Co Quaternary ammonium compounds
GB0020721D0 (en) * 2000-08-22 2000-10-11 Merck Sharp & Dohme Therapeutic agents
ES2289116T3 (es) * 2001-05-24 2008-02-01 Eli Lilly And Company Nuevos derivados de pirrol como agentes farmaceuticos.
BR0314302A (pt) 2002-09-18 2005-07-05 Pfizer Producs Inc Compostos de pirazol como inibidores do fator de crescimento trnasformante (tgf)
AU2003290734A1 (en) * 2002-11-27 2004-06-23 Eli Lilly And Company Novel compounds as pharmaceutical agents
JP5131990B2 (ja) 2006-01-31 2013-01-30 アレイ バイオファーマ、インコーポレイテッド キナーゼ阻害剤およびその使用方法
AU2010299483B2 (en) * 2009-09-24 2014-08-28 Sun Pharmaceutical Industries Limited Process for the preparation of sorafenib tosylate
US8080568B1 (en) * 2010-06-29 2011-12-20 Ewha University - Industry Collaboration Foundation 2-pyridyl substituted imidazoles as therapeutic ALK5 and/or ALK4 inhibitors
EP3277673B1 (en) 2015-04-01 2022-05-04 Rigel Pharmaceuticals, Inc. Tgf-beta inhibitors
RU2737737C2 (ru) * 2016-06-13 2020-12-02 Джинфлит Терапьютикс (Шанхай) Инк. АЛЬФА- И БЕТА-НЕНАСЫЩЕННОЕ АМИДНОЕ СОЕДИНЕНИЕ - ПРОИЗВОДНОЕ БЕНЗОТРИАЗОЛА, ПРИМЕНЯЕМОЕ В КАЧЕСТВЕ ИНГИБИТОРА TGF-βRI

Also Published As

Publication number Publication date
AU2018383853A1 (en) 2020-07-30
RU2750702C1 (ru) 2021-07-01
CN111479809B (zh) 2021-10-29
JP7028977B2 (ja) 2022-03-02
US20210079021A1 (en) 2021-03-18
CA3085498C (en) 2023-04-18
EP3725786B1 (en) 2023-08-23
EP3725786A4 (en) 2021-04-28
KR20200106163A (ko) 2020-09-11
US11236112B2 (en) 2022-02-01
EP3725786A1 (en) 2020-10-21
ES2960412T3 (es) 2024-03-04
PT3725786T (pt) 2023-10-17
CN111479809A (zh) 2020-07-31
JP2021506791A (ja) 2021-02-22
WO2019114792A1 (zh) 2019-06-20
BR112020011602A2 (pt) 2020-12-08
AU2018383853B2 (en) 2021-06-03
KR102507328B1 (ko) 2023-03-07
CA3085498A1 (en) 2019-06-20

Similar Documents

Publication Publication Date Title
DK3661921T3 (da) Selektive hæmmere af nlrp3-inflammasom
DK3248967T3 (da) Krystallinsk form af et benzimidazolderivat og en fremstillingsfremgangsmåde herfor
DK3259253T3 (da) Sulfonylureaer og relaterede forbindelser og brug af samme
DK3470400T3 (da) Krystallinske former af ozanimod og ozanimodhydrochlorid samtfremgangsmåder til fremstilling deraf
DK3548033T3 (da) Forbindelser og deres fremgangsmåde til anvendelse
DK3356529T3 (da) Sammensætninger og fremgangsmåder til hæmning af genekspression af lpa
IL282552A (en) Crystalline forms of MNK inhibitors
DK3292134T3 (da) Metode til dyrkning af akkermansia
HUE064559T2 (hu) MAGL inhibitor kristályos formája
DK3484469T3 (da) Sammensætninger og fremgangsmåder til potentiering af antimikrober
DK3144001T3 (da) Sammensætninger af selenoorganiske forbindelser og fremgangsmåder til anvendelse deraf
IL286218A (en) Solid state forms of ripretinib
DK3262046T3 (da) Salte af pi3k-inhibitor og fremgangsmåder til fremstilling deraf
DK3894012T3 (da) Krystallinske former og saltformer af en kinasehæmmer
DK3067355T3 (da) Krystaller af diazabicyclooctanderivat og fremgangsmåde til fremstilling af krystaller af diazabicyclooctanderivat
DK3447051T3 (da) Fremgangsmåde til fremstilling af tyrosinkinaseinhibitor og derivat deraf
DK3551625T3 (da) Heterocykliske inhibitorer af mct4
DK3429998T3 (da) Fremgangsmåde til fremstilling af quinolin-2-yl-phenylaminderivater og disses salte
DK3215493T3 (da) Syntese af copanlisib og dihydrochloridsalt deraf
DK3412674T3 (da) Trifluoracetatsalt af en TLR7-agonist og krystalform B deraf, fremstillingsfremgangsmåder og anvendelser
DK3205653T3 (da) Krystalform af bisulfat af jak-hæmmer og fremgangsmåde til fremstilling deraf
ZA202007037B (en) Crystal form of c-met inhibitor and salt form thereof and preparation method therefor
IL269626A (en) Crystalline salt forms of boc-d-arg-dmt-lys-(boc)-phe-nh2
LT3519394T (lt) Kalkobutrolio modifikacijos kristalinės formos gavimo būdas
ZA201904460B (en) Inhibitors of nhe-mediated antiport